Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C64H83N17O13 |
| Molecular Weight | 1298.4499 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=N)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)NNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](CC4=CC=C(O)C=C4)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](CC5=CNC6=C5C=CC=C6)C(N)=O
InChI
InChIKey=BDPDXFSIFWZPCE-PHOVXGMNSA-N
InChI=1S/C64H83N17O13/c1-34(2)26-48(57(88)73-46(20-13-25-69-63(67)68-5)56(87)74-47(55(66)86)29-39-32-70-44-18-11-9-16-42(39)44)78-64(94)81-80-61(92)50(27-37-14-7-6-8-15-37)77-62(93)54(35(3)82)79-60(91)52(31-53(65)85)76-59(90)51(30-40-33-71-45-19-12-10-17-43(40)45)75-58(89)49(72-36(4)83)28-38-21-23-41(84)24-22-38/h6-12,14-19,21-24,32-35,46-52,54,70-71,82,84H,13,20,25-31H2,1-5H3,(H2,65,85)(H2,66,86)(H,72,83)(H,73,88)(H,74,87)(H,75,89)(H,76,90)(H,77,93)(H,79,91)(H,80,92)(H3,67,68,69)(H2,78,81,94)/t35-,46+,47+,48+,49-,50+,51-,52+,54+/m1/s1
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Characterization of the cloned guinea pig leukotriene B4 receptor: comparison to its human orthologue. | 1999 Sep 10 |
|
| A novel hepatointestinal leukotriene B4 receptor. Cloning and functional characterization. | 2000 Dec 29 |
|
| Leukotrienes modulate cytokine release from dendritic cells. | 2005 Dec |
|
| 4-Hydroxynonenal enhances MMP-9 production in murine macrophages via 5-lipoxygenase-mediated activation of ERK and p38 MAPK. | 2010 Jan 15 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
TAK-683
Created by
admin on Sat Dec 16 11:42:35 GMT 2023 , Edited by admin on Sat Dec 16 11:42:35 GMT 2023
|
PRIMARY | MedKoo CAT NO: 202723, CAS NO: 872719-49-8Description: TAK-683 is an investigational peptide derivative of metastin that has been shown preclinically to be a potent metastin/GPR54 agonist both in vitro and in vivo. Administration of TAK-683 to male rats for 4 or 8 weeks has been shown to deplete GnRH in the hypothalamus and to reduce plasma FSH, LH and testosterone concentrations. The metastin analogue TAK-683 may be a promising candidate for further investigation in clinical trials in prostate cancer. A related metastin analogue, TAK-448, is also being evaluated in animal studies and in phase 1 clinical trials in prostate cancer (last updated: 7/13/2015). | ||
|
49787129
Created by
admin on Sat Dec 16 11:42:35 GMT 2023 , Edited by admin on Sat Dec 16 11:42:35 GMT 2023
|
PRIMARY | |||
|
K56X3P8P9Q
Created by
admin on Sat Dec 16 11:42:35 GMT 2023 , Edited by admin on Sat Dec 16 11:42:35 GMT 2023
|
PRIMARY | |||
|
872719-49-8
Created by
admin on Sat Dec 16 11:42:35 GMT 2023 , Edited by admin on Sat Dec 16 11:42:35 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
![Structure of L-Tryptophanamide, N-acetyl-D-tyrosyl-D-tryptophyl-L-asparaginyl-L-threonyl-L-phenylalanyl-2-azaglycyl-L-leucyl-N5-[imino(methylamino)methyl]-L-ornithyl-, acetate (1:1)](/img/3e88ccd2-f258-4b77-9ad6-77b7ffe1bc9f.svg "Structure of L-Tryptophanamide, N-acetyl-D-tyrosyl-D-tryptophyl-L-asparaginyl-L-threonyl-L-phenylalanyl-2-azaglycyl-L-leucyl-N5-[imino(methylamino)methyl]-L-ornithyl-, acetate (1:1)")